Core Viewpoint - Tianjin Development Holdings Limited has entered into three new main agreements with Tianjin Pharmaceutical Group Co., Ltd., aimed at renewing existing continuing connected transactions that will expire on December 31, 2025 [1] Group 1: Agreements Overview - The agreements include a sales main agreement, a processing entrustment agreement, and a pharmaceutical procurement agreement, collectively referred to as the 2025 Tianjin Pharmaceutical Main Agreements, effective from January 1, 2026, to December 31, 2026 [1] - The proposed annual caps for the agreements are set at RMB 90 million for sales transactions, RMB 70 million for processing entrustment transactions, and RMB 20 million for pharmaceutical procurement transactions [2] Group 2: Compliance and Monitoring - The company has implemented internal control measures, and the transactions will be regularly reviewed by external auditors and independent non-executive directors to ensure fair pricing and terms that are not more favorable than those offered to independent third parties [2]
天津发展（00882.HK）披露重续与天津市医药集团有限公司的持续关连交易，12月23日股价上涨0.41%